Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 2
2011 4
2012 15
2013 12
2014 11
2015 27
2016 65
2017 64
2018 55
2019 34
2020 68
2021 50
2022 36
2023 37
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Results by year

Filters applied: . Clear all
Page 1
Elotuzumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999843 Free Books & Documents. Review.
No information is available on the clinical use of elotuzumab during breastfeeding. Because elotuzumab is a large protein molecule with a molecular weight of 148,100 Da the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in th …
No information is available on the clinical use of elotuzumab during breastfeeding. Because elotuzumab is a large protein mole …
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Dimopoulos MA, et al. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762. N Engl J Med. 2018. PMID: 30403938 Clinical Trial.
METHODS: Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone al …
METHODS: Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were rando …
Elotuzumab for multiple myeloma.
[No authors listed] [No authors listed] Aust Prescr. 2022 Aug;45(4):138-139. doi: 10.18773/austprescr.2022.040. Epub 2022 Jul 7. Aust Prescr. 2022. PMID: 36110178 Free PMC article. Review. No abstract available.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Lonial S, et al. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. N Engl J Med. 2015. PMID: 26035255 Free article. Clinical Trial.
METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). ...Median progression-free survival in the elotuzumab gr …
METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (el
Elotuzumab.
[No authors listed] [No authors listed] 2017 Mar 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Mar 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644037 Free Books & Documents. Review.
Elotuzumab is a humanized monoclonal antibody to cell surface receptor SLAMF7 which is used in combination with other antineoplastic agents in the therapy of multiple myeloma. Elotuzumab has been implicated in rare instances of transient, marked serum enzyme elevati
Elotuzumab is a humanized monoclonal antibody to cell surface receptor SLAMF7 which is used in combination with other antineoplastic
Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Hum Vaccin Immunother. 2017. PMID: 28604269 Free PMC article. Review.
Although preclinical data looked very promising, elotuzumab monotherapy did not result in objective clinical responses in patients with relapsed/refractory multiple myeloma. ...Currently, there are several clinical trials ongoing investigating the role of elotuzumab
Although preclinical data looked very promising, elotuzumab monotherapy did not result in objective clinical responses in patients wi …
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Dimopoulos MA, et al. J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815. Epub 2022 Aug 12. J Clin Oncol. 2023. PMID: 35960908 Free PMC article. Clinical Trial.
PURPOSE: In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patients with relapsed/refract …
PURPOSE: In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132), elotuzumab combined with pomalidomide/dexamet …
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Lamb YN. Lamb YN. Drugs. 2018 Sep;78(14):1481-1488. doi: 10.1007/s40265-018-0969-4. Drugs. 2018. PMID: 30232695 Review.
The clinical benefit of elotuzumab was maintained over the longer term ( 4 years' minimum follow-up); final overall survival data are awaited. Health-related quality of life was not negatively impacted by the addition of elotuzumab. Elotuzumab combination the …
The clinical benefit of elotuzumab was maintained over the longer term ( 4 years' minimum follow-up); final overall survival data are …
Elotuzumab in multiple myeloma.
Bruzzese A, Martino EA, Vigna E, Iaccino E, Mendicino F, Lucia E, Olivito V, Filippelli G, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Expert Opin Biol Ther. 2023 Jan;23(1):7-10. doi: 10.1080/14712598.2022.2145882. Epub 2022 Nov 14. Expert Opin Biol Ther. 2023. PMID: 36373842 No abstract available.
The Clinical Pharmacology of Elotuzumab.
Passey C, Sheng J, Mora J, Tendolkar A, Robbins M, Dodge R, Roy A, Bello A, Gupta M. Passey C, et al. Clin Pharmacokinet. 2018 Mar;57(3):297-313. doi: 10.1007/s40262-017-0585-6. Clin Pharmacokinet. 2018. PMID: 28779463 Review.
Elotuzumab antidrug antibodies occurred in 18.5% of patients treated with ELd or elotuzumab plus bortezomib and dexamethasone, but were generally transient and did not affect elotuzumab efficacy or safety. A monotherapy study indicated elotuzumab does
Elotuzumab antidrug antibodies occurred in 18.5% of patients treated with ELd or elotuzumab plus bortezomib and dexamethasone,
423 results